Has momelotinib been officially launched in China?

Momelotinib is an oral small molecule kinase inhibitor mainly used to treat primary myelofibrosis and related myeloproliferative diseases. It regulates abnormal cell signaling by inhibiting JAK1 and JAK2 kinases, thereby alleviating disease symptoms and improving patients' quality of life. Although molotinib has been clinically studied in many places around the world, as of now, the drug has not yet been officially approved for marketing in mainland China.

Since molotinib is not yet on the market in China, patients who need to use the drug usually need to rely on formal and compliant overseas drug purchase channels. When purchasing through overseas channels, patients should pay special attention to the source and authenticity of drugs and choose reputable suppliers to ensure drug safety and efficacy. At the same time, medication should be used under the guidance of a professional doctor to ensure that the treatment plan is scientific and reasonable.

In overseas markets, the US version of the original drug molotinib is more expensive, with the latest selling price being around 200,000 yuan, which is a considerable expense for most patients. The high price is mainly due to various factors such as research and development costs, patent protection, and import taxes. Therefore, patients should comprehensively consider their economic conditions and treatment needs when deciding to purchase.

In addition, the generic version of molotinib produced by Lucius Pharmaceuticals has been approved for marketing by the Ministry of Health of Laos. The ingredients of this version are basically the same as the original drug, and the quality and efficacy are guaranteed to a certain extent. The specification of the generic version is 100mg*30 tablets. The latest price is about 2,000 yuan, which is affordable and has become an alternative choice for many patients. Generally speaking, when choosing molotinib, patients should consider their actual situation, weigh the source, price and efficacy of the drug, and formulate a reasonable medication plan.

Reference materials:https://en.wikipedia.org/wiki/Momelotinib